Want to see ICU full AI Analyst Report?
ICU Stock Chart & Stats
$3.12
$0.04(1.07%)
At close: 4:00 PM EDT
$3.12
$0.04(1.07%)
Day’s Range― - ―
52-Week Range$2.07 - $12.50
Previous CloseN/A
Volume1.09K
Average Volume (3M)66.19K
Market Cap
$13.79M
Enterprise Value$8.16
Total Cash (Recent Filing)$6.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 18, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.91
Shares Outstanding4,406,841
10 Day Avg. Volume49,597
30 Day Avg. Volume66,194
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)4.78
Price to Sales (P/S)40.32
P/FCF Ratio-3.66
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.68
Revenue Forecast (FY)$1.95M
Bulls Say, Bears Say
Bulls Say
High-growth Revenue With Strong Gross MarginsRapid revenue growth and pharmaceutical-like gross margins indicate early product-market traction and attractive unit economics. If commercial adoption continues, the high-margin model could allow incremental revenue to contribute meaningfully toward future operating leverage.
Expanding Pediatric Hospital AdoptionDoubling the customer base among leading pediatric hospitals provides evidence of growing clinical acceptance and commercial reach. These reference sites may support broader physician confidence, recurring utilization and a stronger foundation for future expansion.
Regulatory, Reimbursement And Clinical ProgressBreakthrough status, dedicated billing and substantial pivotal-trial enrollment reduce key barriers to eventual commercialization. Together with the completed SAVE Registry, these milestones strengthen validation while advancing the pathway toward adult AKI approval.
Bears Say
Large Losses And Persistent Cash BurnLosses remain many times larger than revenue, and cash outflows closely track reported losses. Without materially faster revenue scaling or lower costs, the company may need additional financing, limiting financial flexibility and increasing execution pressure.
Rising Expenses And Shareholder DilutionClinical expansion and overhead are increasing faster than the current revenue base, worsening operating leverage. The sharp rise in shares outstanding also shows reliance on equity funding, which can dilute existing holders before profitability is established.
Trial Execution And Adult Commercialization DependenceSlower enrollment could delay completion and the planned late-2027 PMA submission. Because the larger adult opportunity depends on successful clinical and regulatory outcomes, delays or unfavorable results would prolong cash needs and constrain long-term growth.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $2.07 and its highest was $12.50 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $13.79M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is Nov 18, 2026 which is in 77 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on Aug 12, 2026. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$0.97 by $0.06.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Overvalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -0.95.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 4,406,841 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$0.91 in its last earnings report, beating expectations of -$0.97. Following the earnings report the stock price went down -5.655%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SeaStar Medical Holding
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
ICU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented meaningful commercial and clinical progress: strong year-over-year revenue growth (+82% Q2), expanded hospital adoption (20 of top 50 pediatric centers), important regulatory and reimbursement milestones (Breakthrough Designation, ICD-10-PCS code), and solid enrollment progress in the NEUTRALIZE-AKI pivotal trial (~65.8% enrolled). Offsetting these positives are materially higher operating expenses, a larger net loss in absolute dollars, a notable cash decline (−41.7% from year-end 2025) and an enrollment cadence that is slower than ideal — all of which create near-term execution and funding risks. On balance, the trajectory is encouraging commercially and clinically, but the company must manage cash runway and accelerate enrollment to realize the larger adult opportunity.View all ICU earnings summariesTechnical Analysis
Ownership Overview
3.10% Insiders
1.20% Mutual Funds
<0.01% Other Institutional Investors
94.89% Public Companies and
Individual Investors